Cempra Inc.


Cowen Raises Cempra Price Target On The Back Of Phase 3 Solitaire Oral Topline Results

In a research report published today, Cowen analyst Ritu Baral maintained an Outperform rating on Cempra (NASDAQ:CEMP) and raised his price target to $35 …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts